Story Brooke
Known title: DirectorCIK: 0001866136
Associated companies
Transaction History
| LIVN | ▼ Sell | Open Market | 2,300 | $187K | 9/4/2026 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 4,042 | $0 | 6/15/2026 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 486 | $39K | 6/15/2026 | View on chart |
| LIVN | ▼ Sell | Open Market | 250 | $13K | 11/18/2025 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 3,416 | $0 | 6/15/2025 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 410 | $19K | 6/15/2025 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 2,680 | $0 | 6/15/2024 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 584 | $31K | 6/15/2024 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 1,725 | $0 | 9/15/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 345 | $20K | 9/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
LivaNova Shares Rise on Barclays Overweight Rating
Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.
LivaNova Shares Rise on Barclays Overweight Rating. Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.